A liver disease diagnostics company commercialising new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis.
Exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals.
Tests revolutionise care and treatment for the at-risk, chronic liver disease population.
Product:
HCC Biomarker Panel
For early-stage primary liver cancer (hepatocellular carcinoma)
